DEA's 5-Part Medical-Use Test Under Fire as Marijuana Rescheduling Hearing Heads to August 17 Briefs
ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Key Takeaways
- ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Mentioned
Key Intelligence
Key Facts
- 1Post-hearing briefs in the DEA marijuana rescheduling proceeding are due August 17, 2026, after which Administrative Law Judge Derek C. Julius will issue a recommendation on the proposed rule.
- 2DEA scientist Dr. Luli Akinfiresoye testified on the agency's traditional five-part test for determining 'currently accepted medical use,' raising questions about reproducible chemistry, adequate safety information, and evidence from adequate and well-controlled studies for state-licensed marijuana products.
- 3MMJ International Holdings CEO Duane Boise stated that the key question from the hearing is 'whether the evidentiary record actually supports the government's state licensed marijuana pathway,' signaling that the rescheduling proposal's legal foundation is under threat.
- 4The federal government's proposal moves marijuana to Schedule III but only for products distributed through qualifying state medical-marijuana programs—a novel, channel-dependent approach not previously tested under the Controlled Substances Act.
- 5Hearing testimony also addressed diversion risks from state programs and the broader question of whether widespread state-level use can substitute for the standardized safety evidence and federal regulatory controls expected of FDA-approved medicines.
- 6The ALJ's recommendation, while non-binding, will heavily influence the DEA's final decision and could set a precedent for how the CSA's medical-use standard is applied in future drug scheduling proceedings.
the most important question may no longer be whether marijuana reaches Schedule III—but whether the evidentiary record actually supports the government's state licensed marijuana pathway.
Following the DEA rescheduling hearing before ALJ Julius
Analysis
For legal professionals tracking administrative drug law, the DEA's marijuana rescheduling hearing has surfaced a fundamental tension between statutory evidentiary requirements and a policy-driven carve-out. The testimony of DEA scientist Dr. Luli Akinfiresoye, which highlighted gaps in reproducible chemistry and controlled clinical trials, poses a direct challenge to the government's assertion that state medical programs alone can establish 'currently accepted medical use.' This proceeding could redefine how agencies interpret the CSA's scheduling criteria under political pressure.
The Administrative Law Judge (ALJ) hearing on the Drug Enforcement Administration's (DEA) proposal to reschedule marijuana from Schedule I to Schedule III has concluded, and the built record is exposing a deep tension that could shape the future of federal cannabis regulation. With post-hearing briefs due August 17, 2026, and a recommendation from ALJ Derek C. Julius expected shortly thereafter, the proceeding has become more than a simple determination of whether marijuana meets the Controlled Substances Act (CSA) criteria for a less restrictive schedule. According to Duane Boise, CEO of MMJ International Holdings—a company pursuing FDA-approved pharmaceutical cannabinoid products—the hearing developed testimony that challenges the very architecture of the government's plan: extending Schedule III status exclusively to marijuana distributed through qualifying state medical-marijuana programs, rather than granting it to the substance itself. This carve-out, crafted to accommodate ongoing state-level legalization without fully conceding federal acceptance, now faces scrutiny under the DEA's own traditional five-part test for determining a currently accepted medical use (CAMU).
For legal professionals tracking administrative drug law, the DEA's marijuana rescheduling hearing has surfaced a fundamental tension between statutory evidentiary requirements and a policy-driven carve-out.
The heart of the legal drama lies in the testimony of DEA scientist Dr. Luli Akinfiresoye. She addressed the CAMU analysis under the standard framework that the DEA has applied in prior rescheduling proceedings, a framework that requires, among other elements, that the chemistry of the substance be known and reproducible, that there be adequate safety studies, and that efficacy be demonstrated through adequate and well-controlled clinical studies. According to notes from MMJ's representatives, her testimony raised pointed questions about whether state-licensed marijuana programs—which lack uniform product standardization, centralized safety monitoring, and prospective randomized controlled trials—can satisfy those rigorous evidentiary standards. The hearing also probed data on diversion from state programs and the ability of widespread non-medical use to substitute for the clinical evidence typically demanded of prescription medicines. These exchanges have moved the proceeding's center of gravity: the most consequential question may no longer be whether marijuana merits Schedule III status in the abstract, but whether the evidentiary record actually supports the government's novel state-licensed pathway.
This is a significant legal inflection point. When the DEA and the Department of Health and Human Services (HHS) initiated the rescheduling process in 2024, they signaled a willingness to bring marijuana under federal regulatory oversight while preserving the states' autonomy. The idea was to place marijuana in Schedule III—alongside drugs like ketamine and testosterone—but only when it is produced and dispensed under a qualifying state medical program, effectively creating a hybrid federal-state authorization ladder. However, the CSA does not explicitly contemplate such a bifurcated scheduling approach based on the distribution channel. The statute asks whether the substance has a CAMU in treatment in the United States, without conditioning that determination on the quality of state regulatory frameworks. By focusing the hearing on the reliability of state-licensed products, the testimony may be laying a foundation for the ALJ to recommend that the DEA either expand the rescheduling to all marijuana that can meet the CAMU standard or reject the current evidentiary record as insufficient.
What to Watch
The stakes are high for the entire cannabis ecosystem. Pharmaceutical companies like MMJ International Holdings, which are pursuing traditional FDA approval for cannabinoid medicines, watch these proceedings closely because a successful state-licensed Schedule III pathway could create a parallel market that bypasses the costly and time-consuming clinical trial process. This would raise complex intellectual property, market access, and regulatory fairness issues. Conversely, state-licensed dispensaries and their operators fear that a recommendation rejecting the pathway could leave them in continued legal limbo, exposed to federal enforcement despite state legality. The ALJ's recommendation, though non-binding, will carry significant weight with the DEA Administrator, and its reasoning could influence federal courts if the decision is ultimately challenged.
Looking ahead, the August 17 briefs will crystallize these arguments. Parties are likely to submit sharply contrasting views on the evidentiary weight of state program data versus traditional clinical trials, and on the precedential effect of using state legality as a proxy for federal medical acceptance. The recommendation itself, expected in the following weeks or months, will be a landmark document. If ALJ Julius concludes that the record does not support the state-licensed pathway, the DEA could be forced to reconsider the scope of its proposed rule—potentially broadening it to all marijuana products that can be shown to have a CAMU, or narrowing it to only those products that have completed the FDA process. Alternatively, the agency could attempt to adopt the recommendation while still preserving the state-licensed carve-out by finding that widespread state-level use, even if scientifically imperfect, satisfies a more flexible interpretation of the CAMU standard. Either outcome will likely be litigated. The proceeding thus offers a real-time case study in how administrative law navigates the collision between evolving social policy and the rigid scientific gatekeeping embedded in the CSA.
Timeline
Timeline
Post-Hearing Briefs Due
Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
Sources
Sources
Based on 2 source articles- nashvilleherald.comA Look Into the ALJ Crystal Ball : What the DEA Marijuana Hearing Record May Be Telling UsAug 10, 2026
- pittsburghstar.comA Look Into the ALJ Crystal Ball : What the DEA Marijuana Hearing Record May Be Telling UsAug 10, 2026
Cite This Page
"DEA's 5-Part Medical-Use Test Under Fire as Marijuana Rescheduling Hearing Heads to August 17 Briefs." Legal & RegTech Intelligence Brief, August 10, 2026. https://getlegalbrief.com/story/dea-marijuana-rescheduling-legal-tensions
How we covered this story
Every story in our legal coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the legal space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled legal-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |